BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Adult Hodgkin lymphoma AND MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7
1540 results:

  • 1. Efficacy and Nuances of Precision Molecular Engineering for hodgkin's Disease to a Gene Therapeutic Approach.
    Qadir MI; Ahmed B; Hussain N
    Crit Rev Immunol; 2024; 44(5):41-50. PubMed ID: 38618727
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas.
    Polgarova K; Trneny M
    Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-hodgkin lymphoma patients treated with R-CHOP.
    Dhar S; Chakravarti M; Ganguly N; Saha A; Dasgupta S; Bera S; Sarkar A; Roy K; Das J; Bhuniya A; Ghosh S; Sarkar M; Hajra S; Banerjee S; Pal C; Saha B; Mukherjee KK; Baral R; Bose A
    Front Immunol; 2023; 14():1303959. PubMed ID: 38304256
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell lymphoma: Real-World Data Analysis.
    Ip A; Mutebi A; Wang T; Jun M; Kalsekar A; Navarro FR; Wang A; Kamalakar R; Sacchi M; Elliott B
    Adv Ther; 2024 Mar; 41(3):1226-1244. PubMed ID: 38302846
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Analysis of Notch1 protein expression in methotrexate-associated lymphoproliferative disorders.
    Okatani T; Nishimura MF; Egusa Y; Yoshida S; Nishimura Y; Nishikori A; Yoshino T; Yamamoto H; Sato Y
    J Clin Exp Hematop; 2024 Mar; 64(1):1-9. PubMed ID: 38281745
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Bispecific antibodies in indolent B-cell lymphomas.
    Radhakrishnan VS; Davies AJ
    Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Consensus recommendations on the management of toxicity associated with CD3×cd20 bispecific antibody therapy.
    Crombie JL; Graff T; Falchi L; Karimi YH; Bannerji R; Nastoupil L; Thieblemont C; Ursu R; Bartlett N; Nachar V; Weiss J; Osterson J; Patel K; Brody J; Abramson JS; Lunning M; Shah NN; Ayed A; Kamdar M; Parsons B; Caimi P; Flinn I; Herrera A; Sharman J; McKenna M; Armand P; Kahl B; Smith S; Zelenetz A; Budde LE; Hutchings M; Phillips T; Dickinson M
    Blood; 2024 Apr; 143(16):1565-1575. PubMed ID: 38252906
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [Clinical and pathological characteristics and prognosis analysis of gray zone lymphoma].
    Liu SZ; Zong XP; Cai WZ; He HJ; Ma ZX; Li JQ; Li CX; Wu DP
    Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(1):69-73. PubMed ID: 38178771
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly
    Takaura K; Ando H; Ganoza ER
    Nihon Yakurigaku Zasshi; 2024; 159(1):61-68. PubMed ID: 38171842
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
    Cabrero M; López-Corral L; Jarque I; de la Cruz-Vicente F; Pérez-López E; Valcárcel D; Sanz J; Espigado I; Ortí G; Martín-Calvo C; de la Serna J; Caballero D;
    Bone Marrow Transplant; 2024 Mar; 59(3):359-365. PubMed ID: 38167647
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Case Report: CD19 CAR T-cell therapy following autologous stem cell transplantation: a successful treatment for R/R cd20-negative transformed follicular lymphoma with
    Zhang J; Cai D; Gao R; Miao Y; Cui Y; Liu Z; Zhang H; Yan X; Su N
    Front Immunol; 2023; 14():1307242. PubMed ID: 38143763
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Loss of cd20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
    Schuster SJ; Huw LY; Bolen CR; Maximov V; Polson AG; Hatzi K; Lasater EA; Assouline SE; Bartlett NL; Budde LE; Matasar MJ; Koeppen H; Piccione EC; Wilson D; Wei MC; Yin S; Penuel E
    Blood; 2024 Feb; 143(9):822-832. PubMed ID: 38048694
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Rare primary pulmonary mucosa-associated lymphoid tissue lymphoma misdiagnosed with tuberculosis: A case report.
    Gu M; Ji D; Lu Y; Ping G; Yan C
    Medicine (Baltimore); 2023 Nov; 102(46):e36125. PubMed ID: 37986314
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: A nationwide population-based cohort study.
    Allouchery M; Brunet K; Tomowiak C; Singier A; Pambrun E; Pariente A; Bezin J; Pérault-Pochat MC; Salvo F
    Mycoses; 2024 Jan; 67(1):e13676. PubMed ID: 37984556
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Sequential antigen loss and branching evolution in lymphoma after CD19- and cd20-targeted T-cell-redirecting therapy.
    Duell J; Leipold AM; Appenzeller S; Fuhr V; Rauert-Wunderlich H; Da Via M; Dietrich O; Toussaint C; Imdahl F; Eisele F; Afrin N; Grundheber L; Einsele H; Weinhold N; Rosenwald A; Topp MS; Saliba AE; Rasche L
    Blood; 2024 Feb; 143(8):685-696. PubMed ID: 37976456
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-hodgkin lymphoma.
    Ikoma Y; Nakamura N; Kitagawa J; Miwa T; Takada E; Matsumoto T; Shibata Y; Nakamura H; Kanemura N; Kasahara S; Hara T; Sawada M; Tsurumi H; Shimizu M
    Hematol Oncol; 2024 Jan; 42(1):e3236. PubMed ID: 37932900
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
    Izutsu K; Kumode T; Yuda J; Nagai H; Mishima Y; Suehiro Y; Yamamoto K; Fujisaki T; Ishitsuka K; Ishizawa K; Ikezoe T; Nishikori M; Akahane D; Fujita J; Dinh M; Soong D; Noguchi H; Buchbjerg JK; Favaro E; Fukuhara N
    Cancer Sci; 2023 Dec; 114(12):4643-4653. PubMed ID: 37921363
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Progressively transformed germinal center-like follicular T-cell lymphoma:a clinicopathological analysis of 14 cases].
    Zheng YY; Xie JL; Zhang YL; Zhou XG
    Zhonghua Bing Li Xue Za Zhi; 2023 Nov; 52(11):1144-1150. PubMed ID: 37899321
    [No Abstract]    [Full Text] [Related]  

  • 19. Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine.
    Faria C; Gava F; Gravelle P; Valero JG; Dobaño-López C; Van Acker N; Quelen C; Jalowicki G; Morin R; Rossi C; Lagarde JM; Fournié JJ; Ysebaert L; Laurent C; Pérez-Galán P; Bezombes C
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899130
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory cd20
    Munoz J; Flinn IW; Cohen JB; Sachs J; Exter B; Ranger A; Harris P; Payumo F; Nath R; Hamadani M; Westin JR; Bachanova V
    Transplant Cell Ther; 2024 Feb; 30(2):241.e1-241.e8. PubMed ID: 37898374
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 77.